

Industry Insight **Clinical Trials in India**

February 2010



Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza, Behind Image Hospital, Ameerpet, Hyderabad- 500 073, India
Tel: +91-40-23430203-07, Fax: +91-40-23430201, E-mail: info@cygnusindia.com
Website: www.cygnusindia.com

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by **Cygnus Business Consulting & Research** (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

SYNOPSIS

Clinical Trials market in India has shown significant growth symptoms in the recent past. Clinical research experienced over 84% growth during 2006-2008 and it has its own merit in regards to further prospect considering global clinical market is growing at 12%. Clinical research industry in India touched US\$258 million in 2008, up from US\$140 million in 2006. An estimate shows that clinical research in India is expected to be US\$320 million by 2009. The cost of conducting clinical trials in India, for instance, is 20 to 60 per cent of the cost in developed countries. Not surprisingly, about 20 to 30 per cent of the clinical development activity is now outsourced to developing countries such as India. Currently, there are more than 150 CROs in India, out of which 20 comply with ICH-GCP guidelines. The leading players in India include Clinigene International, Vimta Labs Ltd, and Lotus labs, besides multinationals like Quintiles Spectral, Pharmanet, SIRO Clinpharm and Clintec, etc.

In view of the growth potential and India's strength in pharmaceuticals to qualify for clinical trials Cygnus has come out with an updated version of the Clinical trials report. The report has total 9 chapters and all chapters are covered in such a fashion that one can understand all aspects of clinical trials industry in India well. This report mostly captures secondary information collected from various reliable information sources covering market information, company specific vital information, issues and challenges, growth drivers and future outlook.

The report will be useful for research analysts in the clinical research space, investors interested in clinical research based companies, students for clinical research who want to pursue career in CROs and various pharma companies who want to understand Indian clinical research industry in India.

No of Pages: 308

No of Figures: 09

No of Tables: 07

CONTENTS

| | |
|-----------------------------------------------------------|-----------|
| EXECUTIVE SUMMARY | 11 |
| HIGHLIGHTS | 14 |
| 1. INTRODUCTION | 16 |
| 1.1 A Brief History | 16 |
| 1.2 Effectiveness and Safety | 20 |
| 1.3 Clinical Trials: Benefits galore | 22 |
| 1.3.1 Research and Innovation..... | 22 |
| 1.3.2 Indian companies increase their R&D spending..... | 23 |
| 1.3.3 Investigational New Drug application (IND)..... | 24 |
| 1.4 Global Scenario | 25 |
| 1.5 Indian Scenario | 26 |
| 1.5.1 Rising tide of research and clinical trials..... | 28 |
| 1.5.2 India as a destination for CROs..... | 29 |
| 1.5.3 Potential of CRO industry..... | 30 |
| 1.5.4 Field Trials (Clinical Trials)..... | 30 |
| 1.5.5 Major Diseases..... | 31 |
| 1.5.6 Infrastructure facilities..... | 31 |
| 1.5.7 Competitors in the sector..... | 32 |
| 1.5.8 Laboratory Trials (Pre-clinical trials)..... | 33 |
| 1.5.9 Recent Trends..... | 33 |
| 1.5.10 Trends in Drug Development..... | 35 |
| 1.5.11 Regulatory Developments..... | 38 |
| 1.5.12 Ethical Review Boards..... | 39 |
| 2. MARKET SCENARIO | 40 |
| 2.1 Global Scenario | 40 |
| 2.1.1 Laboratory-developed Tests..... | 41 |
| 2.1.2 Inspections..... | 41 |
| 2.1.3 Education and Training Requirements..... | 41 |
| 2.1.4 Quality Control..... | 41 |
| 2.2 R&D Expenditure | 42 |
| 2.3 Drug withdrawals/Clinical Trial failures | 44 |
| 2.4 Research on Drug Price Controls | 44 |
| 2.4.1 Loss of Future Drug Therapy..... | 45 |

| | |
|--------------------------------------------------------------------|-----------|
| 2.4.2 Slowdown in Drug Availability | 45 |
| 2.5 Indian Scenario | 45 |
| 2.5.1 Indian Companies..... | 48 |
| 2.5.2 Multinational Companies..... | 48 |
| 2.5.3 Business model (Models of clinical trials outsourcing) | 49 |
| 2.5.4 Target customers | 50 |
| 2.5.5 R&D Budget Break up | 50 |
| 2.5.6. Advantages offered by India in Clinical trials domain | 51 |
| 2.5.7 Outsourcing Clinical trials | 52 |
| 2.5.8 Clinical Trial components | 55 |
| 2.5.9 Market related factors | 58 |
| 3. MAJOR PLAYERS | 62 |
| 3.1 The Players | 62 |
| Listed in BSE/NSE..... | 64 |
| 3.1.1 Clinigene..... | 64 |
| 3.1.2 Dr. Reddy's Laboratories Limited..... | 67 |
| 3.1.3 GlaxoSmithKline | 70 |
| 3.1.4 Lupin Limited | 73 |
| 3.1.5 Novartis | 76 |
| 3.1.6 Pfizer Limited | 78 |
| 3.1.7 Daiichi Sankyo | 82 |
| 3.1.8 Torrent Pharmaceuticals Limited | 85 |
| 3.1.9 Vimta Labs Limited | 88 |
| 3.1.10 Cadila healthcare..... | 91 |
| Unlisted in BSE/NSE | 94 |
| 3.1.11 Asian Clinical Trials Limited..... | 94 |
| 3.1.12 Bioserve Clinical Research Pvt. Ltd..... | 97 |
| 3.1.13 Clininvent Research Pvt. Ltd. | 100 |
| 3.1.14 ClinTech International..... | 103 |
| 3.1.15 Eli Lilly and Company (India) Pvt. Ltd | 106 |
| 3.1.16 iGATE Clinical Research International..... | 108 |
| 3.1.17 Intas Pharmaceuticals | 110 |
| 3.1.18 Johnson & Johnson, India | 113 |
| 3.1.19 Lambda Therapeutic Research Ltd..... | 116 |
| 3.1.20 Lotus Labs Pvt. Ltd. | 118 |
| 3.1.21 Matrix Laboratories Ltd..... | 121 |
| 3.1.22 Merck Limited | 123 |
| 3.1.23 Novo Nordisk India Private Ltd. | 126 |
| 3.1.24 Pharmanet | 128 |
| 3.1.25 Quintiles Research (India) Private Limited..... | 131 |

| | |
|------------------------------------------------------------------------------------|------------|
| 3.1.26 Reliance Clinical Research Services | 134 |
| 3.1.27 Roche India Ltd. | 136 |
| 3.1.28 Sanofi-Aventis (Aventis Pharma Limited) | 139 |
| 3.1.29 Siro Clinpharm Pvt Ltd..... | 141 |
| 3.1.30 Supper Religare Laboratories Ltd..... | 143 |
| 3.1.31 Sristek..... | 146 |
| 3.1.32 Synchron Research Pvt. Ltd. | 150 |
| 3.2 Support services | 153 |
| 3.2.1 Companies entering into support services | 153 |
| 3.2.2 IT-pharma ventures | 154 |
| 3.2.3 Other IT/ITES companies' bio-initiatives..... | 154 |
| 3.2.4 Future of support services | 155 |
| 4. TECHNOLOGY | 156 |
| 4.1 Drug Development..... | 156 |
| 4.2 Biochemistry of the Drugs..... | 157 |
| 4.3 Drug Design..... | 157 |
| 4.3.1 The challenges in drug design | 158 |
| 4.3.2 Computers in drug design | 160 |
| 4.3.3 RACHEL Software Package | 161 |
| 4.4 Animal Studies..... | 163 |
| 4.5 Field Studies | 163 |
| 4.6 Bioavailability (BA) / Bioequivalence (BE) studies | 165 |
| 4.6.1 Types of studies | 166 |
| 4.6.2 Facilities for Conducting Bioavailability and/Or Bioequivalence Studies..... | 168 |
| 4.7 Recent Trends in Technology | 170 |
| 5. GROWTH DRIVERS | 173 |
| 5.1 Claims of Superiority | 173 |
| 5.2 Availability of Patients | 174 |
| 5.3 Infrastructure Facilities..... | 175 |
| 5.3.1 Availability of Animal Houses | 175 |
| 5.3.2 Hospitals | 176 |
| 5.3.3 Facilities for Clinical Trials..... | 176 |
| 5.3.4 Biotechnology Laboratories..... | 178 |
| 5.4 Drug development and price control..... | 180 |
| 5.5 Reduction in R&D expenses | 181 |
| 5.6 Decrease in Time-to-Market Clinical Trials..... | 182 |

| | |
|-----------------------------------------------------------------------|------------|
| 5.7 Regulations and Support from Local Bodies | 182 |
| 5.8 FDA Approval | 183 |
| 5.8.1 Clinical Trials and FDA | 184 |
| 5.8.2 Clinical Trial Process | 184 |
| 6. CRITICAL SUCCESS FACTORS | 188 |
| 6.1 Infrastructure | 188 |
| 6.2 Research Design | 189 |
| 6.3 Speed and Quality of Trials | 190 |
| 6.4 Professionally Trained Manpower | 191 |
| 6.5 Hospitals | 191 |
| 6.6 Role of Radiology | 191 |
| 6.7 Product Pricing and Market Analysis | 193 |
| 6.8 Drug Imports | 193 |
| 6.9 Multiple tasks in approvals | 195 |
| 6.10 Government Procedures/Sanctions | 195 |
| 6.11 Obstacles for Indian Biosimilar players | 196 |
| 6.12 Capacity Planning for Drug Developers | 197 |
| 7. REGULATORY ISSUES | 198 |
| 7.1 Government Regulations | 198 |
| 7.1.1 FDA | 198 |
| 7.2 Patent Regime | 199 |
| 7.2.1 Importance of IPR | 200 |
| 7.3 Customs Duty | 201 |
| 7.4 GATT / TRIPS / WTO | 201 |
| 7.5 Clinical Evaluation of Herbal Remedies and Medicinal Plants | 202 |
| 7.5.1 Categories of Herbal Products | 203 |
| 7.5.2 Guidelines | 203 |
| 7.6 Unsafe Drugs | 205 |
| 7.7 Industry's Growing Influence over Research | 205 |
| 7.8 Academia & Industry – Eroding Boundaries | 206 |
| 7.9 Regulatory System in India | 206 |
| 7.9.1 Exemption of Customs Duty | 209 |
| 7.9.2 Tax benefit | 210 |

| | |
|---------------------------------------------------------------------------------|------------|
| 7.9.3 Role of IACUC | 210 |
| 7.9.4 India Exempts Some Clinical Research from Service Tax..... | 211 |
| 7.10 Regulation of Ethical Issues | 211 |
| 7.10.1 Ethics of Patenting DNA | 212 |
| 7.10.2 Mental Disorders and Genetics..... | 212 |
| 7.10.3 Animal-to-Human Transplants: Ethics of Xenotransplantation | 213 |
| 7.10.4 Human Tissue: Ethical and Legal Issues | 213 |
| 7.10.5 Clinical Trials without Ethical Review | 214 |
| 7.11 The Fair Prescription Drug Competition Act of 2007 | 215 |
| 7.12 Relationships With Hospitals for Trial Sponsors | 216 |
| 7.13 CLINICAL Trials with Controlled drugs | 216 |
| 7.14 Conclusion..... | 217 |
| 8. ISSUES AND CHALLENGES | 219 |
| 8.1 Training for Clinical Trials | 219 |
| 8.1.1 Training Opportunities | 220 |
| 8.2 Clinical Trials - Design & Management..... | 220 |
| 8.2.1 Good Clinical Practices (GCP) | 221 |
| 8.3 Quality of Clinical Trial Data | 222 |
| 8.4 Finding people for trials is always difficult..... | 222 |
| 8.5 Segmenting Physicians | 223 |
| 8.6 Protecting Research and Research Participants..... | 224 |
| 8.7 Ethical Problems | 224 |
| 8.7.1 The role of ethics in clinical trials..... | 225 |
| 8.7.2 Three major ethical problems | 225 |
| 8.7.3 Scientific and Ethical Standards | 225 |
| 8.8 Illegal Clinical Trials | 226 |
| 8.9 Studies in the Developing World | 226 |
| 8.10 Data Protection..... | 227 |
| 8.11 Assessing Risks and Benefits | 227 |
| 8.12 Host Country’s Capacity to Review and Conduct Clinical Trials | 228 |
| 8.13 Additional FDA guidelines for conducting trials | 229 |
| 8.13.1 Clinical Trials Conducted Outside United States | 229 |
| 8.13.2 Clinical Trial Registration | 230 |
| 8.13.3 Computerized Clinical Research Systems | 232 |
| 8.14 Clinical Trials in India - Challenges | 233 |

| | |
|--------------------------------------------------------|------------|
| 8.14.1 Shortage of trained manpower | 233 |
| 8.14.2 Segmenting Physicians | 233 |
| 8.14.3 Addressing the challenges..... | 236 |
| 9. FUTURE OUTLOOK..... | 238 |
| Annexure 1 | 241 |
| BIBLIOGRAPHY | 241 |
| Annexure 2 | 242 |
| Glossary..... | 242 |
| Annexure 3 | 251 |
| Good Clinical Practices (GCP) | 251 |
| Annexure 4 | 270 |
| A Comparison of FDA versus ICH Regulations..... | 270 |
| Annexure 5 | 273 |
| Good Manufacturing Practices..... | 273 |
| Annexure 6 | 296 |
| A New Chapter Opens | 296 |
| Annexure 7 | 303 |

LIST OF FIGURES

- Figure 1.1: Active global clinical studies (INDs)
- Figure 1.2: Global clinical trials expected growth
- Figure 1.3: Global CRO market -2008
- Figure 1.4: India Clinical trials expected growth
- Figure 2.1: NMEs and BLAs drug approvals
- Figure 2.2: Allocation of R&D investments-2008
- Figure 2.3: R&D budget break up in percentage
- Figure 5.1: Transition probabilities for clinical phase
- Figure 9.1: India clinical trials market projections (2010-14)

LIST OF TABLES

Table 1.1: R&D Expenditure (2008-09) Rs in billion

Table 2.1: Ranking by disease-wise in drug development

Table 2.2: R&D Expenditure in 2007& 2008

Table 2.3: strength and weakness of services offered by CRO in India and china

Table 2.4: Leading Indian contract research organizations

Table 5.1: Top R&D spenders-2008

Table7.1: List of drugs withdrawn from commercial activities